- Home
- TRVI vs VIR Comparison
TRVI vs VIR Comparison
Compare TRVI & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRVI
- VIR
- Stock Information
- Founded
- TRVI 2011
- VIR 2016
- Country
- TRVI United States
- VIR United States
- Employees
- TRVI N/A
- VIR N/A
- Industry
- TRVI Biotechnology: Pharmaceutical Preparations
- VIR Biotechnology: Pharmaceutical Preparations
- Sector
- TRVI Health Care
- VIR Health Care
- Exchange
- TRVI Nasdaq
- VIR Nasdaq
- Market Cap
- TRVI 725.7M
- VIR 706.4M
- IPO Year
- TRVI 2019
- VIR 2019
- Fundamental
- Price
- TRVI $8.07
- VIR $4.79
- Analyst Decision
- TRVI Strong Buy
- VIR Strong Buy
- Analyst Count
- TRVI 9
- VIR 11
- Target Price
- TRVI $20.72
- VIR $25.73
- AVG Volume (30 Days)
- TRVI 2.9M
- VIR 1.5M
- Earning Date
- TRVI 11-05-2025
- VIR 10-30-2025
- Dividend Yield
- TRVI N/A
- VIR N/A
- EPS Growth
- TRVI N/A
- VIR N/A
- EPS
- TRVI N/A
- VIR N/A
- Revenue
- TRVI N/A
- VIR $19,000,000.00
- Revenue This Year
- TRVI N/A
- VIR N/A
- Revenue Next Year
- TRVI N/A
- VIR $11.08
- P/E Ratio
- TRVI N/A
- VIR N/A
- Revenue Growth
- TRVI N/A
- VIR N/A
- 52 Week Low
- TRVI $2.36
- VIR $4.16
- 52 Week High
- TRVI $9.92
- VIR $14.45
- Technical
- Relative Strength Index (RSI)
- TRVI 53.13
- VIR 45.84
- Support Level
- TRVI $6.93
- VIR $5.04
- Resistance Level
- TRVI $9.92
- VIR $5.39
- Average True Range (ATR)
- TRVI 0.76
- VIR 0.34
- MACD
- TRVI 0.11
- VIR 0.01
- Stochastic Oscillator
- TRVI 37.96
- VIR 29.45
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.